Microperimetry is a valuable tool for assessing changes in visual function following voretigene neparvovec-rzyl gene therapy.
Microperimetry precisely tracks vision changes in rare hereditary blindness patients treated with gene therapy, filling a measurement gap for this now-treatable condition.
This study validates microperimetry as a sensitive tool to measure visual function changes in RPE65-associated retinal dystrophy patients treated with voretigene gene therapy (Luxturna), filling a gap in outcome measurement for this rare but now treatable condition. Relevant to ongoing gene therapy monitoring and future trial endpoint development.
What the study was
- Study design
- Observational outcomes assessment study
- Population
- Patients with RPE65-associated retinal dystrophy treated with voretigene neparvovec-rzyl (Luxturna) gene therapy
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Ophthalmic Genetics
Why it surfaced
RPE65 retinal dystrophy is a rare disease with an approved gene therapy; outcome measurement tools are needed for post-marketing surveillance and future trials.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.